GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avivagen Inc (TSXV:VIV) » Definitions » Equity-to-Asset

Avivagen (TSXV:VIV) Equity-to-Asset : -33.94 (As of Jul. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avivagen Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avivagen's Total Stockholders Equity for the quarter that ended in Jul. 2023 was C$-9.27 Mil. Avivagen's Total Assets for the quarter that ended in Jul. 2023 was C$0.27 Mil. Therefore, Avivagen's Equity to Asset Ratio for the quarter that ended in Jul. 2023 was -33.94.

The historical rank and industry rank for Avivagen's Equity-to-Asset or its related term are showing as below:

TSXV:VIV' s Equity-to-Asset Range Over the Past 10 Years
Min: -33.94   Med: -1   Max: 0.7
Current: -33.94

During the past 13 years, the highest Equity to Asset Ratio of Avivagen was 0.70. The lowest was -33.94. And the median was -1.00.

TSXV:VIV's Equity-to-Asset is ranked worse than
99.08% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs TSXV:VIV: -33.94

Avivagen Equity-to-Asset Historical Data

The historical data trend for Avivagen's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avivagen Equity-to-Asset Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -1.73 -2.19 -1.14 -4.38

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.17 -4.38 -12.52 -25.57 -33.94

Competitive Comparison of Avivagen's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Avivagen's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avivagen's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avivagen's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Avivagen's Equity-to-Asset falls into.



Avivagen Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Avivagen's Equity to Asset Ratio for the fiscal year that ended in Oct. 2022 is calculated as

Equity to Asset (A: Oct. 2022 )=Total Stockholders Equity/Total Assets
=-5.984/1.365
=-4.38

Avivagen's Equity to Asset Ratio for the quarter that ended in Jul. 2023 is calculated as

Equity to Asset (Q: Jul. 2023 )=Total Stockholders Equity/Total Assets
=-9.265/0.273
=-33.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avivagen  (TSXV:VIV) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Avivagen Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Avivagen's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Avivagen (TSXV:VIV) Business Description

Traded in Other Exchanges
Address
100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc is a Canadian-based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's health defenses. The company's products are based on OxC-beta Technology. Its geographical segments include the Philippines, which is the key revenue driver; Mexico; Thailand; United States; Malaysia; Taiwan; Brazil; and others.
Executives
Jeffrey Jay Kraws Director

Avivagen (TSXV:VIV) Headlines

From GuruFocus

1Q20 Results: Telefônica Brasil S.A.

By PRNewswire PRNewswire 05-06-2020

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 05-30-2022

3Q20 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 10-28-2020

4Q21 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 02-23-2022

4Q20 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 02-24-2021

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 07-09-2022

1Q22 Results: Telef�nica Brasil S.A.

By PRNewswire PRNewswire 06-19-2022